scholarly journals Study on Missing People Search Method on Follow-up of Breast Cancer Cohort

2021 ◽  
Vol 187 ◽  
pp. 586-591
Author(s):  
Yang Guangcheng ◽  
Su Xiao ◽  
Boran Wang ◽  
Wang Ying ◽  
Chang Fei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Search Method ◽  
Breast Cancer Cohort ◽  
People Search

scholarly journals Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience

2015 ◽  
Vol 33 (4) ◽  
pp. 340-348 ◽  
Author(s):  
Antonio C. Wolff ◽  
Amanda L. Blackford ◽  
Kala Visvanathan ◽  
Hope S. Rugo ◽  
Beverly Moy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cumulative Incidence ◽  
Early Stage ◽  
Myelogenous Leukemia ◽  
Early Stage Breast Cancer ◽  
Individual Risk ◽  
Breast Cancer Cohort ◽  
Adjuvant Breast Cancer

Purpose Outcomes for early-stage breast cancer have improved. First-generation adjuvant chemotherapy trials reported a 0.27% 8-year cumulative incidence of myelodysplastic syndrome/acute myelogenous leukemia. Incomplete ascertainment and follow-up may have underestimated subsequent risk of treatment-associated marrow neoplasm (MN). Patients and Methods We examined the MN frequency in 20,063 patients with stage I to III breast cancer treated at US academic centers between 1998 and 2007. Time-to-event analyses were censored at first date of new cancer event, last contact date, or death and considered competing risks. Cumulative incidence, hazard ratios (HRs), and comparisons with Surveillance, Epidemiology, and End Results estimates were obtained. Marrow cytogenetics data were reviewed. Results Fifty patients developed MN (myeloid, n = 42; lymphoid, n = 8) after breast cancer (median follow-up, 5.1 years). Patients who developed MN had similar breast cancer stage distribution, race, and chemotherapy exposure but were older compared with patients who did not develop MN (median age, 59.1 v 53.9 years, respectively; P = .03). Two thirds of patients had complex MN cytogenetics. Risk of MN was significantly increased after surgery plus chemotherapy (HR, 6.8; 95% CI, 1.3 to 36.1) or after all modalities (surgery, chemotherapy, and radiation; HR, 7.6; 95% CI, 1.6 to 35.8), compared with no treatment with chemotherapy. MN rates per 1,000 person-years were 0.16 (surgery), 0.43 (plus radiation), 0.46 (plus chemotherapy), and 0.54 (all three modalities). Cumulative incidence of MN doubled between years 5 and 10 (0.24% to 0.48%); 9% of patients were alive at 10 years. Conclusion In this large early-stage breast cancer cohort, MN risk after radiation and/or adjuvant chemotherapy was low but higher than previously described. Risk continued to increase beyond 5 years. Individual risk of MN must be balanced against the absolute survival benefit of adjuvant chemotherapy.

scholarly journals 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

BMJ ◽  
2005 ◽  
Vol 330 (7485) ◽  
pp. 217 ◽  
Author(s):  
Gianni Bonadonna ◽  
Angela Moliterni ◽  
Milvia Zambetti ◽  
Maria Grazia Daidone ◽  
Silvana Pilotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Operable Breast Cancer ◽  
Breast Cancer Cohort

PO-1089 Long-term follow-up of a single-center neuroendocrine breast cancer cohort

2021 ◽  
Vol 161 ◽  
pp. S906
Author(s):  
P. Loap ◽  
F. Laki ◽  
P. Beuzeboc ◽  
A. Fourquet ◽  
Y. Kirova
Keyword(s):  
Breast Cancer ◽  
Single Center ◽  
Breast Cancer Cohort ◽  
Long Term Follow Up

Optimizing Breast Cancer Follow-up Care: Diagnostic Value and Costs of Additional Routine Breast Ultrasound

2010 ◽  
Vol 31 (S 01) ◽  
Author(s):  
S Wojcinski ◽  
A Farrokh ◽  
U Hille ◽  
E Hirschauer ◽  
W Schmidt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Value ◽  
Breast Ultrasound ◽  
Follow Up Care
Sign in / Sign up

Export Citation Format

Share Document